 <h1>Cycrin Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>medroxyprogesterone</i></p><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li>
<li>FAQ</li></ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about medroxyprogesterone. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Cycrin.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to medroxyprogesterone: oral tablet</i></p><p>Other dosage forms:</p><ul><li>intramuscular suspension</li></ul><h3>Warning</h3><p class="blackboxWarning-title">Oral route (Tablet)</p><p>Estrogen plus progestin therapy should not be used for the prevention of cardiovascular disease or dementia. Studies have demonstrated an increased risk of DVT, pulmonary embolism, stroke and myocardial infarction in postmenopausal women during treatment with daily oral conjugated estrogens combined with medroxyPROGESTERone acetate, relative to placebo. Studies have also demonstrated estrogen plus progestin increases risk of developing probable dementia in postmenopausal women 65 years of age or older. It is unknown whether this finding applies to younger postmenopausal women. An increased risk of invasive breast cancer has also been found in studies. In the absence of comparable data, these risks should be assumed to be similar for other doses of estrogens and progestins, and other combinations and dosage forms of estrogens and progestins. Progestins with estrogens should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman.</p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, medroxyprogesterone (the active ingredient contained in Cycrin) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking medroxyprogesterone:</p><p>
<i>Incidence not known</i>
</p><ul>
<li>Abdominal or stomach pain</li>
<li>absent, missed, or irregular menstrual periods</li>
<li>anxiety</li>
<li>blurred vision</li>
<li>breast pain or tenderness</li>
<li>changes in skin color</li>
<li>chills</li>
<li>clay-colored stools</li>
<li>cough</li>
<li>dark urine</li>
<li>decrease in amount of urine</li>
<li>diarrhea</li>
<li>difficulty swallowing</li>
<li>dizziness or lightheadedness</li>
<li>eye pain</li>
<li>fainting</li>
<li>fast heartbeat</li>
<li>fever</li>
<li>headache</li>
<li>hives or welts, itching, redness, swelling, or skin rash</li>
<li>large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or sex organs</li>
<li>loss of appetite</li>
<li>menstrual changes</li>
<li>nausea</li>
<li>noisy, rattling breathing</li>
<li>pain in the chest, groin, or legs, especially the calves</li>
<li>pain, tenderness, or swelling of the foot or leg</li>
<li>puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue</li>
<li>severe, sudden headache</li>
<li>shortness of breath</li>
<li>slurred speech</li>
<li>stopping of menstrual bleeding</li>
<li>sudden loss of coordination</li>
<li>sudden, severe weakness or numbness in the arm or leg</li>
<li>sudden, unexplained shortness of breath</li>
<li>swelling of the fingers, hands, feet, or lower legs</li>
<li>troubled breathing at rest</li>
<li>unexpected or excess milk flow from the breasts</li>
<li>unpleasant breath odor</li>
<li>unusual tiredness or weakness</li>
<li>vaginal bleeding or spotting</li>
<li>vision changes</li>
<li>vomiting of blood</li>
<li>weight gain</li>
<li>yellow eyes or skin</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of medroxyprogesterone may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>Incidence not known</i>
</p><ul>
<li>Blemishes on the skin</li>
<li>discouragement</li>
<li>feeling sad or empty</li>
<li>hair loss, thinning of hair</li>
<li>increased hair growth, especially on the face</li>
<li>irritability</li>
<li>lack of appetite</li>
<li>loss of interest or pleasure</li>
<li>nervousness</li>
<li>pimples</li>
<li>sleepiness or unusual drowsiness</li>
<li>tiredness</li>
<li>trouble concentrating</li>
<li>trouble sleeping</li>
<li>weight changes</li>
</ul><p>
<div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to medroxyprogesterone: compounding powder, intramuscular suspension, oral tablet, subcutaneous suspension</i></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Abdominal pain/discomfort (up to 11.2%)</p>
<p><b>Common</b> (1% to 10%): Nausea, bloating, abdominal distention, diarrhea, vomiting, constipation</p>
<p><b>Uncommon</b> (0.1% to 1%): Dry mouth</p>
<p><b>Postmarketing reports</b>: Gastrointestinal disturbances, rectal bleeding<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Very common</b> (10% or more): Amenorrhea (up to 68%), bleeding (up to 57.3%), uterine bleeding irregularities (up to 35%) </p>
<p><b>Common</b> (1% to 10%): Dysmenorrhea, leukorrhea, vaginitis, intermenstrual bleeding, urinary tract infection, vaginal candidiasis, vaginitis, vaginitis bacterial, abnormal cervix smear, metrorrhagia, menometrorrhagia, menstruation irregular, vaginal hemorrhage, erectile dysfunction, genitourinary tract infection, pelvic pain, dyspareunia</p>
<p><b>Frequency not reported</b>: Uterine cervical erosions, cervical discharge, vulvovaginal dryness, premenstrual syndrome, vaginal cyst, ovarian cyst, lack of return to fertility, sensation of pregnancy</p>
<p><b>Postmarketing reports</b>: Unexpected pregnancy, uterine hyperplasia, oligomenorrhea, prolonged anovulation<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Increase weight (up to 37%)</p>
<p><b>Common</b> (1% to 10%): Increased appetite, decreased appetite</p>
<p><b>Uncommon</b> (0.1% to 1%): Diabetes mellitus exacerbated, hypercalcemia, fluid retention</p>
<p><b>Frequency not reported</b>: Elevations of serum calcium and potassium levels, exacerbation of diabetes mellitus</p>
<p><b>Postmarketing reports</b>: Decreased glucose tolerance, changes in appetite, excessive thirst<sup>[Ref]</sup></p><p>Weight gain is more frequently encountered than weight loss during medroxyprogesterone therapy.  In women using intramuscular medroxyprogesterone for contraception, the mean weight gain after one year of therapy is 2.5 kg.  After two, four, and six years, patients gain a mean of 3.7, 6.3, and 7.5 kg, respectively.<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Nervousness (10.8%)</p>
<p><b>Common</b> (1% to 10%): Dizziness</p>
<p><b>Rare</b> (less than 0.1%): Cerebral infarction, somnolence</p>
<p><b>Frequency not reported</b>: Loss of concentration, adrenergic-like effects, migraine, seizure, VII th nerve paralysis, syncope</p>
<p><b>Postmarketing reports</b>: Paralysis, facial palsy, paresthesia, drowsiness<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Headache (up to 16.5%)</p>
<p><b>Common</b> (1% to 10%): Asthenia, fatigue, edema /fluid retention, breast pain, breast tenderness</p>
<p><b>Frequency not reported</b>: Chills, fever, vertigo, breast atrophy, breast mass, nipple exudate bloody, breast enlargement</p>
<p><b>Postmarketing reports</b>: Changes in breast size<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p>The majority of cases of thromboembolic disease during hormonal therapy have been attributed to estrogens and not to progestogens.  However, it has been demonstrated that this drug, at least at high doses, can produce a hypercoagulable state.  Whether or not this contributes to the development of thrombotic events remains unknown.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Hot flashes</p>
<p><b>Uncommon</b> (0.1% to 1%): Cardiac failure congestive, thrombophlebitis</p>
<p><b>Rare</b> (less than 0.1%): Myocardial infarction, embolism, thrombosis, blood pressure increased</p>
<p><b>Frequency not reported</b>: Tachycardia, palpitations</p>
<p><b>Postmarketing reports</b>: Deep vein thrombosis, varicose veins<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Acne, no hair growth/alopecia, rash, hyperhidrosis</p>
<p><b>Uncommon</b> (0.1% to 1%): Hirsutism, urticaria, pruritus, chloasma</p>
<p><b>Frequency not reported</b>: Lipodystrophy acquired, dermatitis, ecchymosis, scleroderma, skin striae, erythema multiforme, erythema nodosum</p>
<p><b>Postmarketing reports</b>: Axillary swelling, excessive sweating and body odor, dry skin, melasma<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Leg cramps, arthralgia, back pain, limb pain, pain in extremity</p>
<p><b>Uncommon</b> (0.1% to 1%): Muscle spasms</p>
<p><b>Frequency not reported</b>: Gluteal infiltration and abscess formation</p>
<p><b>Postmarketing reports</b>: Chest pain, osteoporosis including osteoporotic fractures, loss of bone mineral density, scleroderma<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Common</b> (1% to 10%): Depression, insomnia, anxiety, irritability, decreased libido</p>
<p><b>Uncommon</b> (0.1% to 1%): Euphoria, changes in libido </p>
<p><b>Rare</b> (less than 0.1%): Confusion</p>
<p><b>Frequency not reported</b>: Anorgasmia, emotional disturbance, affective disorder,</p>
<p><b>Postmarketing reports</b>: Increased libido<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Common</b> (1% to 10%): Bronchitis, influenza, nasopharyngitis, pharyngitis, sinusitis, upper respiratory tract infection</p>
<p><b>Uncommon</b> (0.1% to 1%): Pulmonary embolism</p>
<p><b>Frequency not reported</b>: Dysphonia</p>
<p><b>Postmarketing reports</b>: Dyspnea, asthma, hoarseness<sup>[Ref]</sup></p><h3>Endocrine</h3><p><b>Uncommon</b> (0.1% to 1%): Corticoid-like effects</p>
<p><b>Frequency not reported</b>: Cushingoid syndrome, galactorrhea</p>
<p><b>Postmarketing reports</b>: Prevention of lactation with or without hyperprolactinemia<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Uncommon</b> (0.1% to 1%): Abnormal hepatic function, jaundice cholestatic</p>
<p><b>Postmarketing reports</b>: Abnormal liver function test, abnormal hepatic enzyme<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Frequency not reported</b>: Allergic reactions including angioedema, anaphylactic reaction, anaphylactoid reaction<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Frequency not reported</b>: White blood cell count increased, platelet count increased</p>
<p><b>Postmarketing reports</b>: Anemia, blood dyscrasia<sup>[Ref]</sup></p><h3>Local</h3><p><b>Frequency not reported</b>: Injection site abscess, injection site infection, injection site nodule/lump, injection site pain/tenderness, injection site persistent atrophy/indentation/dimpling<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Frequency not reported</b>: Retinal embolism and thrombosis, cataract diabetic, visual impairment<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Frequency not reported</b>: Glycosuria<sup>[Ref]</sup></p><h3>Oncologic</h3><p>A significant increase in the incidence of breast cancer in beagle dogs in addition to an apparent increase in the incidence of endometrial cancer in rhesus monkeys was noted in early animal carcinogenicity studies.<sup>[Ref]</sup></p><p><b>Postmarketing reports</b>: Cervical cancer, breast cancer, endometrial hyperplasia, breast lumps or nipple bleeding, nipple discharge<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Product Information. depo-subQ provera 104 (medroxyPROGESTERone (medroxyprogesterone))." Pfizer U.S. Pharmaceuticals Group, New York, NY. </p><p id="ref_2">2. "Product Information. Depo-Provera (medroxyprogesterone)." Pharmacia and Upjohn, Kalamazoo, MI. </p><p id="ref_3">3. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_4">4. "Product Information. MedroxyPROGESTERone Acetate (medroxyPROGESTERone (medroxyprogesterone))." Greenstone LLC, Peapack, NJ. </p><p id="ref_5">5. "Product Information. Provera (medroxyprogesterone)." Pharmacia and Upjohn, Kalamazoo, MI. </p><p id="ref_6">6. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_7">7. Archer DF, Pickar JH, Bottiglioni F "Bleeding patterns in postmenopausal women taking continuous combined or sequential regimens of conjugated estrogens with medroxyprogesterone acetate." Obstet Gynecol 83 (1994): 686-92</p><p id="ref_8">8. Kora S, Virkar K "Incidence of pregnancy, changes in menstrual pattern, and recovery of  endometrial function after discontinuation of medroxyprogesterone  acetate therapy." Fertil Steril 26 (1975): 121-5</p><p id="ref_9">9. Sapire KE "A study of bleeding patterns with two injectable contraceptives given  postpartum and the effect of two non-hormonal treatments." Adv Contracept 7 (1991): 379-87</p><p id="ref_10">10. Kaunitz AM "Long-acting injectable contraception with depot medroxyprogesterone acetate." Am J Obstet Gynecol 170 (1994): 1543-9</p><p id="ref_11">11. Fraser IS "A survey of different approaches to management of menstrual  disturbances in women using injectable contraceptives." Contraception 28 (1983): 385-97</p><p id="ref_12">12. Fraser IS "Menstrual changes associated with progestogen-only contraception." Acta Obstet Gynecol Scand Suppl 134 (1986): 21-7</p><p id="ref_13">13. Belsey EM "Menstrual bleeding patterns in untreated women and with long-acting  methods of contraception. Task Force on Long-Acting Systemic Agents  for Fertility Regulation." Adv Contracept 7 (1991): 257-70</p><p id="ref_14">14. Mukherjea M, Mukherjee P, Biswas R "Long-term contraception with Depo-Provera: a clinical evaluation." Int J Fertil 25 (1980): 122-6</p><p id="ref_15">15. Woodruff JD, Pickar JH "Incidence of endometrial hyperplasia in postmenopausal women taking conjugated estrogens (Premarin) with medroxyprogesterone acetate or conjugated estrogens alone." Am J Obstet Gynecol 170 (1994): 1213-23</p><p id="ref_16">16. Teichmann AT, Wander HE, Cremer P, et al. "Medroxyprogesterone acetate and lipid metabolic changes." Arzneimittelforschung 37 (1987): 573-77</p><p id="ref_17">17. Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE "Clinical evaluation of two monthly injectable contraceptives and  their effects on some metabolic parameters." Contraception 39 (1989): 619-32</p><p id="ref_18">18. Barnes RB, Roy S, Lobo RA "Comparison of lipid and androgen levels after conjugated estrogen or  depo-medroxyprogesterone acetate treatment in postmenopausal women." Obstet Gynecol 66 (1985): 216-9</p><p id="ref_19">19. Who Task Force on Long-acting Agents for Fertility Regulation "Metabolic side-effects of injectable depot-medroxyprogesterone acetate, 150 mg three-monthly, in undernourished lactating women." Bull World Health Organ 64 (1986): 587-94</p><p id="ref_20">20. Amatayakul K, Sivasomboon B, Thanangkul O "A study of the mechanism of weight gain in medroxyprogesterone  acetate users." Contraception 22 (1980): 605-22</p><p id="ref_21">21. Luciano AA, De Souza MJ, Roy MP, Schoenfeld MJ, Nulsen JC, Halvorson CV "Evaluation of low-dose estrogen and progestin therapy in postmenopausal women." J Reprod Med 38 (1993): 207-14</p><p id="ref_22">22. Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D "Metabolic effects of depot-medroxyprogesterone acetate in long-term  users: a cross-sectional study." Int J Gynaecol Obstet 24 (1986): 291-6</p><p id="ref_23">23. Leiman G "Depo-medroxyprogesterone acetate as a contraceptive agent: its effect  on weight and blood pressure." Am J Obstet Gynecol 114 (1972): 97-102</p><p id="ref_24">24. Grady D,  Yaffe K,  Kristof M,  Lin F,  Richards C,  Barrett-Connor E "Effect of postmenopausal hormone therapy on cognitive function: the Heart and Estrogen/progestin Replacement Study." Am J Med 113 (2002): 543-8</p><p id="ref_25">25. Farag NH,  Nelesen RA,  Parry BL,  Loredo JS,  Dimsdale JE,  Mills PJ "Autonomic and cardiovascular function in postmenopausal women: The effects of estrogen versus combination therapy." Am J Obstet Gynecol 186(5 Pt 1) (2002): 954-61</p><p id="ref_26">26. Bosch X "Depo-Provera contraceptive may increase risk of cardiovascular disease." BMJ 325 (2002): 513</p><p id="ref_27">27. Fukutomi T, Nanasawa T, Yamamoto H, Adachi I, Watanabe T "The induction of a hypercoagulable state by medroxyprogesterone  acetate in breast cancer patients." Jpn J Surg 20 (1990): 665-70</p><p id="ref_28">28. "Hormone replacement therapy." Med Lett Drugs Ther 44 (2002): 78</p><p id="ref_29">29. Astedt B, Jeppsson S, Pandolfi M "Fibrinolytic activity of veins during use of depot  medroxyprogesterone acetate as a contraceptive." Fertil Steril 23 (1972): 489-92</p><p id="ref_30">30. "Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial." JAMA 288 (2002): 321-33</p><p id="ref_31">31. Skouby SO,  Gram J,  Andersen LF,  Sidelmann J,  Petersen KR,  Jespersen J "Hormone replacement therapy: Estrogen and progestin effects on plasma C-reactive protein concentrations." Am J Obstet Gynecol 186(5 Pt 1) (2002): 969-977</p><p id="ref_32">32. Yamamoto H, Noguchi S, Miyauchi K, Inaji H, Imaoka S, Koyama H, Iwanaga T "Changes in hematologic parameters during treatment with  medroxyprogesterone acetate for breast cancer." Jpn J Cancer Res 82 (1991): 420-5</p><p id="ref_33">33. Cundy T, Farquhar CM, Cornish J, Reid IR "Short-term effects of high dose oral medroxyprogesterone acetate on bone density in premenopausal women." J Clin Endocrinol Metab 81 (1996): 1014-7</p><p id="ref_34">34. Cundy T, Evans M, Roberts H, Wattie D, Ames R, Reid IR "Bone density in women receiving depot medroxyprogesterone acetate for  contraception [published erratum appears in BMJ 1991 Jul27;303(6796):220]." BMJ 303 (1991): 13-6</p><p id="ref_35">35. Paiva LC, PintoNeto AM, Faundes A "Bone density among long-term users of medroxyprogesterone acetate as a contraceptive." Contraception 58 (1998): 351-5</p><p id="ref_36">36. Nand SL, Wren BG, Gross BA, Heller GZ "Bone density effects of continuous estrone sulfate and varying doses of medroxyprogesterone acetate." Obstet Gynecol 93 (1999): 1009-13</p><p id="ref_37">37. Bjorn I, Bixo M, Nojd KS, Nyberg S, Backstrom T "Negative mood changes during hormone replacement therapy: A comparison between two progestogens." Am J Obstet Gynecol 183 (2000): 1419-26</p><p id="ref_38">38. Donckier JE, Michel LA, Buysschaert M "Cushing syndrome and medroxyprogesterone acetate" Lancet 335 (1990): 1094</p><p id="ref_39">39. Wortsman J, Hirschowitz JS "Galactorrhea and hyperprolactinemia during treatment of polycystic  ovary syndrome." Obstet Gynecol 55 (1980): 460-3</p><p id="ref_40">40. Siminoski K, Goss P, Drucker DJ "The Cushing syndrome induced by medroxyprogesterone acetate." Ann Intern Med 111 (1989): 758-60</p><p id="ref_41">41. Chaudhury RR, Chompootaweep S, Dusitsin N, Friesen H, Tankeyoon M "The release of prolactin by medroxy-progesterone acetate in human  subjects." Br J Pharmacol 59 (1977): 433-4</p><p id="ref_42">42. Grenfell A, Rudenski A, Watts M, Wiltshire C, Day JL, Gray IP "Cushing's syndrome and medroxyprogesterone acetate" Lancet 336 (1990): 256</p><p id="ref_43">43. Spellacy WN, Buhi WC, Birk SA "Stimulated plasma prolactin levels in women using medroxyprogesterone  acetate or an intrauterine device for contraception." Fertil Steril 26 (1975): 970-81</p><p id="ref_44">44. Learoyd D, McElduff A "Medroxyprogesterone induced Cushing's syndrome." Aust N Z J Med 20 (1990): 824-5</p><p id="ref_45">45. Meyer WJ, 3d  Wiener I, Emory LE, Cole CM, Isenberg N, Fagan CJ, Thompson JC "Cholelithiasis associated with medroxyprogesterone acetate therapy in  men." Res Commun Chem Pathol Pharmacol 75 (1992): 69-84</p><p id="ref_46">46. Riippa P, Kauppila A, Sundstrom H, Vihko R "Hepatic impairment during simultaneous administration of  medroxyprogesterone acetate and tamoxifen in the treatment of  endometrial and ovarian carcinoma." Anticancer Res 4 (1984): 109-12</p><p id="ref_47">47. Zacest R, Cushway A, Haines C, Cox LW "Hypersensitivity reaction to Depo-Provera" Med J Aust 1 (1982): 12</p><p id="ref_48">48. Brooks GG "Anaphylactoid shock with medroxyprogesterone acetate: A case report." J La State Med Soc 126 (1974): 397-9</p><p id="ref_49">49. Lumbiganon P "Depot-medroxyprogesterone acetate (DMPA) and cancer of the endometrium and ovary." Contraception 49 (1994): 203-9</p><p id="ref_50">50. Liang AP, Levenson AG, Layde PM, Shelton JD, Hatcher RA, Potts M, Michelson MJ "Risk of breast, uterine corpus, and ovarian cancer in women receiving  medroxyprogesterone injections." JAMA 249 (1983): 2909-12</p><p id="ref_51">51. "Breast cancer and depot-medroxyprogesterone acetate: a multinational  study. WHO Collaborative Study of Neoplasia and Steroid  Contraceptives" Lancet 338 (1991): 833-8</p><p id="ref_52">52. Lavecchia C "Depot-medroxyprogesterone acetate, other injectable contraceptives, and cervical neoplasia." Contraception 49 (1994): 223-30</p><p id="ref_53">53. Jordan A "Toxicology of depot medroxyprogesterone acetate." Contraception 49 (1994): 189-201</p><p id="ref_54">54. "Depot-medroxyprogesterone acetate (DMPA) and risk of endometrial  cancer. The WHO Collaborative Study of Neoplasia and Steroid  Contraceptives." Int J Cancer 49 (1991): 186-90</p><p id="ref_55">55. "Breast cancer, cervical cancer, and depot medroxyprogesterone  acetate. WHO Collaborative Study of Neoplasia and Steroid  Contraceptives" Lancet 2 (1984): 1207-8</p><p id="ref_56">56. "Depot-medroxyprogesterone acetate (DMPA) and risk of invasive  squamous cell cervical cancer. The WHO Collaborative Study of  Neoplasia and Steroid Contraceptives." Contraception 45 (1992): 299-312</p><p id="ref_57">57. Oberle MW, Rosero-Bixby L, Irwin KL, Fortney JA, Lee NC, Whatley AS, Bonhomme MG "Cervical cancer risk and use of depot-medroxyprogesterone acetate in  Costa Rica." Int J Epidemiol 17 (1988): 718-23</p><p id="ref_58">58. "Depot-medroxyprogesterone acetate (DMPA) and risk of liver cancer.  The WHO Collaborative Study of Neoplasia and Steroid Contraceptives." Int J Cancer 49 (1991): 182-5</p><p id="ref_59">59. Chilvers C "Breast cancer and depot-medroxyprogesterone acetate - a review." Contraception 49 (1994): 211-22</p><p id="ref_60">60. Skegg DC, Noonan EA, Paul C, Spears GF, Meirik O, Thomas DB "Depot medroxyprogesterone acetate and breast cancer." JAMA 273 (1995): 799-807</p><p id="ref_61">61. "Depot-medroxyprogesterone acetate (DMPA) and risk of epithelial  ovarian cancer. The WHO Collaborative Study of Neoplasia and Steroid  Contraceptives." Int J Cancer 49 (1991): 191-5</p></div>
<h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2>
<ul>
<li>Why is my poop green? What does this mean?</li>
<li>My stool has changed color. What does it mean?</li>
</ul>
<div class="more-resources" id="moreResources">
<h2>More about Cycrin (medroxyprogesterone)</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>Drug class: contraceptives</li>
<li>FDA Alerts (1)</li>
</ul>
<h3>Consumer resources</h3>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Depo-Provera, Provera, depo-subQ provera 104</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Abnormal Uterine Bleeding</li>
<li>Amenorrhea</li>
<li>Birth Control</li>
<li>Endometrial Cancer</li>
<li>Endometrial Hyperplasia, Prophylaxis</li>
<li>Endometriosis</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to medroxyprogesterone: compounding powder, intramuscular suspension, oral tablet, subcutaneous suspension</i></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Abdominal pain/discomfort (up to 11.2%)</p><p><b>Common</b> (1% to 10%): Nausea, bloating, abdominal distention, diarrhea, vomiting, constipation</p><p><b>Uncommon</b> (0.1% to 1%): Dry mouth</p><p><b>Postmarketing reports</b>: Gastrointestinal disturbances, rectal bleeding<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Very common</b> (10% or more): Amenorrhea (up to 68%), bleeding (up to 57.3%), uterine bleeding irregularities (up to 35%) </p><p><b>Common</b> (1% to 10%): Dysmenorrhea, leukorrhea, vaginitis, intermenstrual bleeding, urinary tract infection, vaginal candidiasis, vaginitis, vaginitis bacterial, abnormal cervix smear, metrorrhagia, menometrorrhagia, menstruation irregular, vaginal hemorrhage, erectile dysfunction, genitourinary tract infection, pelvic pain, dyspareunia</p><p><b>Frequency not reported</b>: Uterine cervical erosions, cervical discharge, vulvovaginal dryness, premenstrual syndrome, vaginal cyst, ovarian cyst, lack of return to fertility, sensation of pregnancy</p><p><b>Postmarketing reports</b>: Unexpected pregnancy, uterine hyperplasia, oligomenorrhea, prolonged anovulation<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Increase weight (up to 37%)</p><p><b>Common</b> (1% to 10%): Increased appetite, decreased appetite</p><p><b>Uncommon</b> (0.1% to 1%): Diabetes mellitus exacerbated, hypercalcemia, fluid retention</p><p><b>Frequency not reported</b>: Elevations of serum calcium and potassium levels, exacerbation of diabetes mellitus</p><p><b>Postmarketing reports</b>: Decreased glucose tolerance, changes in appetite, excessive thirst<sup>[Ref]</sup></p><p>Weight gain is more frequently encountered than weight loss during medroxyprogesterone therapy.  In women using intramuscular medroxyprogesterone for contraception, the mean weight gain after one year of therapy is 2.5 kg.  After two, four, and six years, patients gain a mean of 3.7, 6.3, and 7.5 kg, respectively.<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Nervousness (10.8%)</p><p><b>Common</b> (1% to 10%): Dizziness</p><p><b>Rare</b> (less than 0.1%): Cerebral infarction, somnolence</p><p><b>Frequency not reported</b>: Loss of concentration, adrenergic-like effects, migraine, seizure, VII th nerve paralysis, syncope</p><p><b>Postmarketing reports</b>: Paralysis, facial palsy, paresthesia, drowsiness<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Headache (up to 16.5%)</p><p><b>Common</b> (1% to 10%): Asthenia, fatigue, edema /fluid retention, breast pain, breast tenderness</p><p><b>Frequency not reported</b>: Chills, fever, vertigo, breast atrophy, breast mass, nipple exudate bloody, breast enlargement</p><p><b>Postmarketing reports</b>: Changes in breast size<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p>The majority of cases of thromboembolic disease during hormonal therapy have been attributed to estrogens and not to progestogens.  However, it has been demonstrated that this drug, at least at high doses, can produce a hypercoagulable state.  Whether or not this contributes to the development of thrombotic events remains unknown.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Hot flashes</p><p><b>Uncommon</b> (0.1% to 1%): Cardiac failure congestive, thrombophlebitis</p><p><b>Rare</b> (less than 0.1%): Myocardial infarction, embolism, thrombosis, blood pressure increased</p><p><b>Frequency not reported</b>: Tachycardia, palpitations</p><p><b>Postmarketing reports</b>: Deep vein thrombosis, varicose veins<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Acne, no hair growth/alopecia, rash, hyperhidrosis</p><p><b>Uncommon</b> (0.1% to 1%): Hirsutism, urticaria, pruritus, chloasma</p><p><b>Frequency not reported</b>: Lipodystrophy acquired, dermatitis, ecchymosis, scleroderma, skin striae, erythema multiforme, erythema nodosum</p><p><b>Postmarketing reports</b>: Axillary swelling, excessive sweating and body odor, dry skin, melasma<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Leg cramps, arthralgia, back pain, limb pain, pain in extremity</p><p><b>Uncommon</b> (0.1% to 1%): Muscle spasms</p><p><b>Frequency not reported</b>: Gluteal infiltration and abscess formation</p><p><b>Postmarketing reports</b>: Chest pain, osteoporosis including osteoporotic fractures, loss of bone mineral density, scleroderma<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Common</b> (1% to 10%): Depression, insomnia, anxiety, irritability, decreased libido</p><p><b>Uncommon</b> (0.1% to 1%): Euphoria, changes in libido </p><p><b>Rare</b> (less than 0.1%): Confusion</p><p><b>Frequency not reported</b>: Anorgasmia, emotional disturbance, affective disorder,</p><p><b>Postmarketing reports</b>: Increased libido<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Common</b> (1% to 10%): Bronchitis, influenza, nasopharyngitis, pharyngitis, sinusitis, upper respiratory tract infection</p><p><b>Uncommon</b> (0.1% to 1%): Pulmonary embolism</p><p><b>Frequency not reported</b>: Dysphonia</p><p><b>Postmarketing reports</b>: Dyspnea, asthma, hoarseness<sup>[Ref]</sup></p><h3>Endocrine</h3><p><b>Uncommon</b> (0.1% to 1%): Corticoid-like effects</p><p><b>Frequency not reported</b>: Cushingoid syndrome, galactorrhea</p><p><b>Postmarketing reports</b>: Prevention of lactation with or without hyperprolactinemia<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Uncommon</b> (0.1% to 1%): Abnormal hepatic function, jaundice cholestatic</p><p><b>Postmarketing reports</b>: Abnormal liver function test, abnormal hepatic enzyme<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Frequency not reported</b>: Allergic reactions including angioedema, anaphylactic reaction, anaphylactoid reaction<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Frequency not reported</b>: White blood cell count increased, platelet count increased</p><p><b>Postmarketing reports</b>: Anemia, blood dyscrasia<sup>[Ref]</sup></p><h3>Local</h3><p><b>Frequency not reported</b>: Injection site abscess, injection site infection, injection site nodule/lump, injection site pain/tenderness, injection site persistent atrophy/indentation/dimpling<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Frequency not reported</b>: Retinal embolism and thrombosis, cataract diabetic, visual impairment<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Frequency not reported</b>: Glycosuria<sup>[Ref]</sup></p><h3>Oncologic</h3><p>A significant increase in the incidence of breast cancer in beagle dogs in addition to an apparent increase in the incidence of endometrial cancer in rhesus monkeys was noted in early animal carcinogenicity studies.<sup>[Ref]</sup></p><p><b>Postmarketing reports</b>: Cervical cancer, breast cancer, endometrial hyperplasia, breast lumps or nipple bleeding, nipple discharge<sup>[Ref]</sup></p><p id="ref_1">1. "Product Information. depo-subQ provera 104 (medroxyPROGESTERone (medroxyprogesterone))." Pfizer U.S. Pharmaceuticals Group, New York, NY. </p><p id="ref_2">2. "Product Information. Depo-Provera (medroxyprogesterone)." Pharmacia and Upjohn, Kalamazoo, MI. </p><p id="ref_3">3. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_4">4. "Product Information. MedroxyPROGESTERone Acetate (medroxyPROGESTERone (medroxyprogesterone))." Greenstone LLC, Peapack, NJ. </p><p id="ref_5">5. "Product Information. Provera (medroxyprogesterone)." Pharmacia and Upjohn, Kalamazoo, MI. </p><p id="ref_6">6. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_7">7. Archer DF, Pickar JH, Bottiglioni F "Bleeding patterns in postmenopausal women taking continuous combined or sequential regimens of conjugated estrogens with medroxyprogesterone acetate." Obstet Gynecol 83 (1994): 686-92</p><p id="ref_8">8. Kora S, Virkar K "Incidence of pregnancy, changes in menstrual pattern, and recovery of  endometrial function after discontinuation of medroxyprogesterone  acetate therapy." Fertil Steril 26 (1975): 121-5</p><p id="ref_9">9. Sapire KE "A study of bleeding patterns with two injectable contraceptives given  postpartum and the effect of two non-hormonal treatments." Adv Contracept 7 (1991): 379-87</p><p id="ref_10">10. Kaunitz AM "Long-acting injectable contraception with depot medroxyprogesterone acetate." Am J Obstet Gynecol 170 (1994): 1543-9</p><p id="ref_11">11. Fraser IS "A survey of different approaches to management of menstrual  disturbances in women using injectable contraceptives." Contraception 28 (1983): 385-97</p><p id="ref_12">12. Fraser IS "Menstrual changes associated with progestogen-only contraception." Acta Obstet Gynecol Scand Suppl 134 (1986): 21-7</p><p id="ref_13">13. Belsey EM "Menstrual bleeding patterns in untreated women and with long-acting  methods of contraception. Task Force on Long-Acting Systemic Agents  for Fertility Regulation." Adv Contracept 7 (1991): 257-70</p><p id="ref_14">14. Mukherjea M, Mukherjee P, Biswas R "Long-term contraception with Depo-Provera: a clinical evaluation." Int J Fertil 25 (1980): 122-6</p><p id="ref_15">15. Woodruff JD, Pickar JH "Incidence of endometrial hyperplasia in postmenopausal women taking conjugated estrogens (Premarin) with medroxyprogesterone acetate or conjugated estrogens alone." Am J Obstet Gynecol 170 (1994): 1213-23</p><p id="ref_16">16. Teichmann AT, Wander HE, Cremer P, et al. "Medroxyprogesterone acetate and lipid metabolic changes." Arzneimittelforschung 37 (1987): 573-77</p><p id="ref_17">17. Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE "Clinical evaluation of two monthly injectable contraceptives and  their effects on some metabolic parameters." Contraception 39 (1989): 619-32</p><p id="ref_18">18. Barnes RB, Roy S, Lobo RA "Comparison of lipid and androgen levels after conjugated estrogen or  depo-medroxyprogesterone acetate treatment in postmenopausal women." Obstet Gynecol 66 (1985): 216-9</p><p id="ref_19">19. Who Task Force on Long-acting Agents for Fertility Regulation "Metabolic side-effects of injectable depot-medroxyprogesterone acetate, 150 mg three-monthly, in undernourished lactating women." Bull World Health Organ 64 (1986): 587-94</p><p id="ref_20">20. Amatayakul K, Sivasomboon B, Thanangkul O "A study of the mechanism of weight gain in medroxyprogesterone  acetate users." Contraception 22 (1980): 605-22</p><p id="ref_21">21. Luciano AA, De Souza MJ, Roy MP, Schoenfeld MJ, Nulsen JC, Halvorson CV "Evaluation of low-dose estrogen and progestin therapy in postmenopausal women." J Reprod Med 38 (1993): 207-14</p><p id="ref_22">22. Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D "Metabolic effects of depot-medroxyprogesterone acetate in long-term  users: a cross-sectional study." Int J Gynaecol Obstet 24 (1986): 291-6</p><p id="ref_23">23. Leiman G "Depo-medroxyprogesterone acetate as a contraceptive agent: its effect  on weight and blood pressure." Am J Obstet Gynecol 114 (1972): 97-102</p><p id="ref_24">24. Grady D,  Yaffe K,  Kristof M,  Lin F,  Richards C,  Barrett-Connor E "Effect of postmenopausal hormone therapy on cognitive function: the Heart and Estrogen/progestin Replacement Study." Am J Med 113 (2002): 543-8</p><p id="ref_25">25. Farag NH,  Nelesen RA,  Parry BL,  Loredo JS,  Dimsdale JE,  Mills PJ "Autonomic and cardiovascular function in postmenopausal women: The effects of estrogen versus combination therapy." Am J Obstet Gynecol 186(5 Pt 1) (2002): 954-61</p><p id="ref_26">26. Bosch X "Depo-Provera contraceptive may increase risk of cardiovascular disease." BMJ 325 (2002): 513</p><p id="ref_27">27. Fukutomi T, Nanasawa T, Yamamoto H, Adachi I, Watanabe T "The induction of a hypercoagulable state by medroxyprogesterone  acetate in breast cancer patients." Jpn J Surg 20 (1990): 665-70</p><p id="ref_28">28. "Hormone replacement therapy." Med Lett Drugs Ther 44 (2002): 78</p><p id="ref_29">29. Astedt B, Jeppsson S, Pandolfi M "Fibrinolytic activity of veins during use of depot  medroxyprogesterone acetate as a contraceptive." Fertil Steril 23 (1972): 489-92</p><p id="ref_30">30. "Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial." JAMA 288 (2002): 321-33</p><p id="ref_31">31. Skouby SO,  Gram J,  Andersen LF,  Sidelmann J,  Petersen KR,  Jespersen J "Hormone replacement therapy: Estrogen and progestin effects on plasma C-reactive protein concentrations." Am J Obstet Gynecol 186(5 Pt 1) (2002): 969-977</p><p id="ref_32">32. Yamamoto H, Noguchi S, Miyauchi K, Inaji H, Imaoka S, Koyama H, Iwanaga T "Changes in hematologic parameters during treatment with  medroxyprogesterone acetate for breast cancer." Jpn J Cancer Res 82 (1991): 420-5</p><p id="ref_33">33. Cundy T, Farquhar CM, Cornish J, Reid IR "Short-term effects of high dose oral medroxyprogesterone acetate on bone density in premenopausal women." J Clin Endocrinol Metab 81 (1996): 1014-7</p><p id="ref_34">34. Cundy T, Evans M, Roberts H, Wattie D, Ames R, Reid IR "Bone density in women receiving depot medroxyprogesterone acetate for  contraception [published erratum appears in BMJ 1991 Jul27;303(6796):220]." BMJ 303 (1991): 13-6</p><p id="ref_35">35. Paiva LC, PintoNeto AM, Faundes A "Bone density among long-term users of medroxyprogesterone acetate as a contraceptive." Contraception 58 (1998): 351-5</p><p id="ref_36">36. Nand SL, Wren BG, Gross BA, Heller GZ "Bone density effects of continuous estrone sulfate and varying doses of medroxyprogesterone acetate." Obstet Gynecol 93 (1999): 1009-13</p><p id="ref_37">37. Bjorn I, Bixo M, Nojd KS, Nyberg S, Backstrom T "Negative mood changes during hormone replacement therapy: A comparison between two progestogens." Am J Obstet Gynecol 183 (2000): 1419-26</p><p id="ref_38">38. Donckier JE, Michel LA, Buysschaert M "Cushing syndrome and medroxyprogesterone acetate" Lancet 335 (1990): 1094</p><p id="ref_39">39. Wortsman J, Hirschowitz JS "Galactorrhea and hyperprolactinemia during treatment of polycystic  ovary syndrome." Obstet Gynecol 55 (1980): 460-3</p><p id="ref_40">40. Siminoski K, Goss P, Drucker DJ "The Cushing syndrome induced by medroxyprogesterone acetate." Ann Intern Med 111 (1989): 758-60</p><p id="ref_41">41. Chaudhury RR, Chompootaweep S, Dusitsin N, Friesen H, Tankeyoon M "The release of prolactin by medroxy-progesterone acetate in human  subjects." Br J Pharmacol 59 (1977): 433-4</p><p id="ref_42">42. Grenfell A, Rudenski A, Watts M, Wiltshire C, Day JL, Gray IP "Cushing's syndrome and medroxyprogesterone acetate" Lancet 336 (1990): 256</p><p id="ref_43">43. Spellacy WN, Buhi WC, Birk SA "Stimulated plasma prolactin levels in women using medroxyprogesterone  acetate or an intrauterine device for contraception." Fertil Steril 26 (1975): 970-81</p><p id="ref_44">44. Learoyd D, McElduff A "Medroxyprogesterone induced Cushing's syndrome." Aust N Z J Med 20 (1990): 824-5</p><p id="ref_45">45. Meyer WJ, 3d  Wiener I, Emory LE, Cole CM, Isenberg N, Fagan CJ, Thompson JC "Cholelithiasis associated with medroxyprogesterone acetate therapy in  men." Res Commun Chem Pathol Pharmacol 75 (1992): 69-84</p><p id="ref_46">46. Riippa P, Kauppila A, Sundstrom H, Vihko R "Hepatic impairment during simultaneous administration of  medroxyprogesterone acetate and tamoxifen in the treatment of  endometrial and ovarian carcinoma." Anticancer Res 4 (1984): 109-12</p><p id="ref_47">47. Zacest R, Cushway A, Haines C, Cox LW "Hypersensitivity reaction to Depo-Provera" Med J Aust 1 (1982): 12</p><p id="ref_48">48. Brooks GG "Anaphylactoid shock with medroxyprogesterone acetate: A case report." J La State Med Soc 126 (1974): 397-9</p><p id="ref_49">49. Lumbiganon P "Depot-medroxyprogesterone acetate (DMPA) and cancer of the endometrium and ovary." Contraception 49 (1994): 203-9</p><p id="ref_50">50. Liang AP, Levenson AG, Layde PM, Shelton JD, Hatcher RA, Potts M, Michelson MJ "Risk of breast, uterine corpus, and ovarian cancer in women receiving  medroxyprogesterone injections." JAMA 249 (1983): 2909-12</p><p id="ref_51">51. "Breast cancer and depot-medroxyprogesterone acetate: a multinational  study. WHO Collaborative Study of Neoplasia and Steroid  Contraceptives" Lancet 338 (1991): 833-8</p><p id="ref_52">52. Lavecchia C "Depot-medroxyprogesterone acetate, other injectable contraceptives, and cervical neoplasia." Contraception 49 (1994): 223-30</p><p id="ref_53">53. Jordan A "Toxicology of depot medroxyprogesterone acetate." Contraception 49 (1994): 189-201</p><p id="ref_54">54. "Depot-medroxyprogesterone acetate (DMPA) and risk of endometrial  cancer. The WHO Collaborative Study of Neoplasia and Steroid  Contraceptives." Int J Cancer 49 (1991): 186-90</p><p id="ref_55">55. "Breast cancer, cervical cancer, and depot medroxyprogesterone  acetate. WHO Collaborative Study of Neoplasia and Steroid  Contraceptives" Lancet 2 (1984): 1207-8</p><p id="ref_56">56. "Depot-medroxyprogesterone acetate (DMPA) and risk of invasive  squamous cell cervical cancer. The WHO Collaborative Study of  Neoplasia and Steroid Contraceptives." Contraception 45 (1992): 299-312</p><p id="ref_57">57. Oberle MW, Rosero-Bixby L, Irwin KL, Fortney JA, Lee NC, Whatley AS, Bonhomme MG "Cervical cancer risk and use of depot-medroxyprogesterone acetate in  Costa Rica." Int J Epidemiol 17 (1988): 718-23</p><p id="ref_58">58. "Depot-medroxyprogesterone acetate (DMPA) and risk of liver cancer.  The WHO Collaborative Study of Neoplasia and Steroid Contraceptives." Int J Cancer 49 (1991): 182-5</p><p id="ref_59">59. Chilvers C "Breast cancer and depot-medroxyprogesterone acetate - a review." Contraception 49 (1994): 211-22</p><p id="ref_60">60. Skegg DC, Noonan EA, Paul C, Spears GF, Meirik O, Thomas DB "Depot medroxyprogesterone acetate and breast cancer." JAMA 273 (1995): 799-807</p><p id="ref_61">61. "Depot-medroxyprogesterone acetate (DMPA) and risk of epithelial  ovarian cancer. The WHO Collaborative Study of Neoplasia and Steroid  Contraceptives." Int J Cancer 49 (1991): 191-5</p><h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2><ul>
<li>Why is my poop green? What does this mean?</li>
<li>My stool has changed color. What does it mean?</li>
</ul><h2>More about Cycrin (medroxyprogesterone)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>Drug class: contraceptives</li>
<li>FDA Alerts (1)</li>
</ul><h3>Consumer resources</h3><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Abnormal Uterine Bleeding</li>
<li>Amenorrhea</li>
<li>Birth Control</li>
<li>Endometrial Cancer</li>
<li>Endometrial Hyperplasia, Prophylaxis</li>
<li>Endometriosis</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>